Precision Target Identification in Neurosurgery: A Validation Case Study

Executive summary

A pharmaceutical company needed to validate its KOL targeting approach in neuro-oncology against an industry-standard benchmark list. We reached a 95%+ match rate on the benchmark’s high-rated targets, found all 8 high-priority targets, and identified 27 emerging leaders the benchmark didn’t list.

Study overview

We tested our approach against an industry-standard list of neurosurgeons, focusing on neuro-oncology specialists. The study covered:

• Analysis of 185 neurosurgeons
• Cross-referencing against 86 benchmark profiles
• Detailed evaluation of expertise in neuro-oncology treatment and research
• Scoring based on 12+ qualification metrics

Key findings

Match rate for high-priority targets

• 95%+ match rate for all benchmark targets rated 7 and above
• All 8 high-priority targets from the benchmark database identified
• 27 further emerging leaders in neuro-oncology research identified, not yet captured in benchmark data

Who we picked up

• Established key opinion leaders (KOLs)
• Emerging researchers with recent publications
• Specialists using newer surgical techniques
• Clinical trial participation

How the data was collected

Publication analysis: peer-reviewed research output, citation impact metrics and clinical trial publications.

Clinical experience tracking: surgical case volumes and specialized procedure types.

Academic impact assessment: teaching positions, research leadership roles and grant funding.

Professional network analysis: conference presentations, society leadership positions and collaborative research.

Why the wider range matters

We returned 35 high-scoring targets against the benchmark’s 8. That wider range is useful rather than oversampling. It:

• Captures rising stars before they become widely recognized
• Identifies specialists in emerging surgical techniques
• Includes researchers advancing neuro-oncology treatment

Conclusion

The validation gave us confidence the approach scales. The real value was the 27 names we hadn’t been tracking. Those are the next generation we needed to start engaging now.

Client, pharmaceutical company

A benchmark shows who is already known. A multi-source approach adds who is coming next.